United Therapeutics Revenue Dips 2% Amid Tyvaso DPI Growth and Nebulized Tyvaso Decline
Event summary
- Total revenues decreased by 2% year-over-year to $781.5 million in Q1 2026, down from $794.4 million in Q1 2025.
- Tyvaso DPI revenues grew by 9% to $330.3 million, while Nebulized Tyvaso revenues declined by 22% to $127.2 million.
- Net income fell by 15% to $274.9 million, with net income per diluted share dropping by 12% to $5.82.
- United Therapeutics announced a $2.0 billion share repurchase program, with $500 million remaining available through March 2027.
The big picture
United Therapeutics is navigating a competitive landscape for inhaled prostacyclins, with its commercial strategy focusing on Tyvaso DPI's resilience. The company's long-term commitment to advancing therapies for cardiopulmonary and respiratory diseases remains a strategic anchor, but the near-term challenge is returning to sequential quarterly revenue growth across its commercial portfolio. The $2.0 billion share repurchase program underscores a commitment to shareholder value, even as revenue trends show mixed results.
What we're watching
- Product Transition
- The shift from Nebulized Tyvaso to Tyvaso DPI will be critical to watch, as the former's decline could offset the latter's growth.
- R&D Investment
- The company's focus on ralinepag DPI and its potential for once-daily dosing could drive future revenue diversification.
- Shareholder Returns
- The pace at which United Therapeutics executes its $2.0 billion share repurchase program will signal confidence in its financial health.
Related topics